One Aspirin a Day Helps Keep Cancer Away

  • cance,Health,Heart Disease,Medicine,New Research
  • smithsonianmag

According to a new paper, around 130,000 deaths from cancer could be prevented in the U.K. alone if 50- to 64-year-olds simply took a low-dose aspirin each day for ten years, theGuardian reports. Taking aspirin, the researchers said, seems to be the most important lifestyle factor after stopping smoking and reducing obesity for lowering cancer risk.

The Queen Mary University of London researchers behind the findings examined the results of more than 200 studies that investigated the potential benefits and harms of regularly taking aspirin, the BBC reports. Aspirin is known to reduce some cancer risk as well as heart attack risk, but it can also cause potentially fatal stomach bleeds. Until now, the medical community has been unsure about whether or not taking aspirin as a therapeutic preventative medication was worth that risk.

The results of the analysis showed that aspirin reduces the risk of death by stomach, bowel and oesophageal cancer by up to 40 percent, the BBC says. Risk of death by breast, prostate and lung cancer was also reduced, but to a lower extent. The beneficial effects, the researchers said, require at least five to 10 years of regular aspirin-taking. Those effects, however, will roll over if a person stops taking aspirin after 10 years, for example.

Aspirin also reduces risk of having a heart attack or dying of a heart attack, the team found. However, while it reduces the risk of having a stroke, it increases the risk of death from stroke by 21 percent, the Guardian explains. It also increased the risk of stomach bleeds among 60-year-olds from 2.2 percent to 3.6 percent. As the BBC puts it, while well over 100,000 lives could be saved if 50-to-64-year-olds took aspirin, around 18,000 lives would be lost due to the side effects. Ultimately, the researchers think that the risk is outweighed by the potential benefits, although they especially advise persons who drink or smoke heavily or who are at high risk of bleeding to speak with their doctor before beginning a long-term aspirin regime, the BBC writes.


This link:http://www.chemcd.com/news/2003.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.